Cim Investment Management Inc. Has $1.39 Million Position in Merck & Co., Inc. (NYSE:MRK)

Cim Investment Management Inc. reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 2.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 17,804 shares of the company’s stock after selling 402 shares during the quarter. Cim Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $1,385,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of MRK. Cowen Prime Advisors LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $31,000. PARK CIRCLE Co lifted its holdings in Merck & Co., Inc. by 100.0% in the 2nd quarter. PARK CIRCLE Co now owns 400 shares of the company’s stock worth $31,000 after purchasing an additional 200 shares during the last quarter. AlphaMark Advisors LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $39,000. Lake Point Wealth Management acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $40,000. Finally, Monumental Financial Group Inc. bought a new position in Merck & Co., Inc. in the 2nd quarter worth approximately $44,000. Hedge funds and other institutional investors own 71.83% of the company’s stock.

NYSE:MRK traded down $0.20 during trading hours on Thursday, reaching $78.75. The company had a trading volume of 391,663 shares, compared to its average volume of 12,310,182. The stock has a 50-day moving average of $76.31 and a two-hundred day moving average of $76.75. Merck & Co., Inc. has a one year low of $70.89 and a one year high of $85.60. The firm has a market capitalization of $199.35 billion, a PE ratio of 36.08, a PEG ratio of 2.16 and a beta of 0.41. The company has a quick ratio of 1.06, a current ratio of 1.31 and a debt-to-equity ratio of 0.72.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Wednesday, July 28th. The company reported $1.31 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.31. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. The firm had revenue of $11.40 billion for the quarter, compared to analysts’ expectations of $11.21 billion. During the same period in the prior year, the business posted $1.37 earnings per share. As a group, sell-side analysts expect that Merck & Co., Inc. will post 5.51 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 7th. Stockholders of record on Wednesday, September 15th were issued a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a dividend yield of 3.30%. The ex-dividend date was Tuesday, September 14th. Merck & Co., Inc.’s payout ratio is presently 43.77%.

Several research analysts have commented on the company. SVB Leerink lifted their price target on Merck & Co., Inc. from $101.00 to $104.00 and gave the stock an “outperform” rating in a research report on Monday, October 4th. Berenberg Bank reaffirmed a “hold” rating and issued a $92.00 price target (up from $86.00) on shares of Merck & Co., Inc. in a research report on Sunday. Zacks Investment Research raised Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 price target on the stock in a research report on Tuesday, August 24th. Truist assumed coverage on Merck & Co., Inc. in a research report on Tuesday, July 27th. They issued a “buy” rating and a $92.00 price target on the stock. Finally, Mizuho assumed coverage on Merck & Co., Inc. in a research report on Friday, October 1st. They issued a “buy” rating and a $100.00 price target on the stock. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Buy” and a consensus target price of $92.18.

Merck & Co., Inc. Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also: Hold Rating

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.